Skip to main content

Deferoxamine Injection

Last Updated: August 16, 2021
Status: Resolved

Products Affected - Description
    • Deferoxamine injection, Pfizer, 500 mg, vial, 4 count, NDC 00409-2336-10 - discontinued
Reason for the Shortage
    • Fresenius Kabi had deferoxamine on shortage due to increased demand.
    • Pfizer had deferoxamine on shortage due to manufacturing delays. The 500 mg vials were discontinued in April 2021.
    • Novartis has Desferal available.
    • Almaject did not provide a reason for the shortage. Almaject discontinued the 500 mg vials in late-2019.
    • Apo-Pharma launched deferoxamine injection in mid-2018.
Available Products
    • Desferal injection, Novartis, 500 mg, vial, 4 count, NDC 00078-0467-91
    • Deferoxamine injection, Almaject, 2 gram, vial, 1 count, NDC 47781-0624-07
    • Deferoxamine injection, Apo-Pharma, 2 gram, vial, 4 count, NDC 52609-4504-06
    • Deferoxamine injection, Apo-Pharma, 500 mg, vial, 4 count, NDC 52609-4505-06
    • Deferoxamine injection, Fresenius Kabi, 2 gram, vial, 1 count, NDC 63323-0599-30
    • Deferoxamine injection, Fresenius Kabi, 500 mg, vial, 1 count, NDC 63323-0597-10
    • Deferoxamine injection, Pfizer, 2 gram, vial, 4 count, NDC 00409-2337-25

Estimated Resupply Dates

    • All marketed presentations are available.

Updated

Updated August 16, 2021 by Michelle Wheeler, PharmD, Drug Information Specialist. Created February 7, 2018 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2021, Drug Information Service, University of Utah, Salt Lake City, UT.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.